Status:
COMPLETED
Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Conditions:
Crohn's Disease (CD)
Ulcerative Colitis (UC)
Eligibility:
All Genders
9-99 years
Brief Summary
This single-center, retrospective study aims to evaluate the effectiveness and safety of upadacitinib (UPA) in Asian pediatric patients with refractory Crohn's disease (CD) and elderly patients with r...
Eligibility Criteria
Inclusion
- Diagnosis of IBD according to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2023)"; Failure of at least two prior biological therapies (anti-TNF/anti-integrin/IL-12/23 inhibitors); Complete baseline and follow-up data (at least 12 weeks))
Exclusion
- Active infection, malignancy, severe cardiovascular disease, or hepatic/renal insufficiency; Pregnancy or breastfeeding; Use of other JAK inhibitors within 30 days prior to baseline)
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2025
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06922331
Start Date
January 1 2023
End Date
March 1 2025
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 515000